OS HR for nivolumab versus docetaxel therapy, according to PD-L1 expression level:(PD-L1 level: HR (95% CI)- ≥1%: 0.69 (0.45 to 1.05)- <1%: 0.58 (0.37 to 0.92)- ≥5%: 0.53 (0.31 to 0.89)- <5%: 0.70 (0.47 to 1.02)- ≥10%: 0.50 (0.28 to 0.89)- <10%: 0.70 (0.48 to 1.01)The tumor PD-L1 status, however, was not found to be of predictive or prognostic value in this particular study. Here, CD274 is linked to neoplasm.